Quarterly ResultMay 14, 2026, 04:18 PM
Alumis Envudeucitinib Phase 3 Data Positive; Q1 Net Loss $93.1M
AI Summary
Alumis Inc. reported a net loss of $93.1 million for Q1 2026, alongside significant clinical advancements for its lead asset, envudeucitinib. Phase 3 data for moderate-to-severe plaque psoriasis demonstrated robust skin clearance and quality-of-life improvements, with an NDA submission planned for Q4 2026. The company also anticipates potentially pivotal Phase 2b data for envudeucitinib in systemic lupus erythematosus in Q3 2026 and has completed a strategic review of its lonigutamab program. Alumis expects its current cash to fund operations into Q4 2027.
Key Highlights
- Envudeucitinib Phase 3 data showed PASI 90 responses of 68.0% and 62.1% by Week 24 in plaque psoriasis.
- Envudeucitinib Phase 3 data showed PASI 100 responses of 41.0% and 39.5% by Week 24.
- Q1 2026 net loss was $93.1 million, an improvement from $99.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $569.5 million as of March 31, 2026.
- Research and development expenses decreased to $81.5 million in Q1 2026 from $96.6 million in Q1 2025.
- NDA submission for envudeucitinib in plaque psoriasis is on track for Q4 2026.
- Potentially pivotal Phase 2b SLE topline data for envudeucitinib is anticipated in Q3 2026.
- Existing cash is expected to fund operating expenses and capital expenditure requirements into Q4 2027.